Literature DB >> 28244153

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.

P Gisondi1, G Altomare2, F Ayala3, F Bardazzi4, L Bianchi5, A Chiricozzi6, A Costanzo7, A Conti8, P Dapavo9, C De Simone10, C Foti11, L Naldi12, A Offidani13, A Parodi14, S Piaserico15, F Prignano16, F Rongioletti17, L Stingeni18, M Talamonti5, G Girolomoni1.   

Abstract

Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2017        PMID: 28244153     DOI: 10.1111/jdv.14114

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  25 in total

1.  Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic.

Authors:  Michele Maria Luchetti; Devis Benfaremo; Anna Campanati; Elisa Molinelli; Monia Ciferri; Serena Cataldi; William Capeci; Marco Di Carlo; Anna Maria Offidani; Fausto Salaffi; Armando Gabrielli
Journal:  Clin Rheumatol       Date:  2018-07-29       Impact factor: 2.980

Review 2.  Treatment Approaches to Moderate to Severe Psoriasis.

Authors:  Paolo Gisondi; Micol Del Giglio; Giampiero Girolomoni
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

3.  Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.

Authors:  Giovanni Damiani; Chiara Franchi; Paolo Pigatto; Andrea Altomare; Alessia Pacifico; Stephen Petrou; Sebastiano Leone; Maria Caterina Pace; Marco Fiore
Journal:  World J Hepatol       Date:  2018-02-27

4.  The Diagnostic-Therapeutic Care Pathway in Psoriasis: Towards ISO 9001:2015 Certification.

Authors:  Federica Veronese; Francesca Graziola; Edoardo Cammarata; Marco Andreassi; Vanessa Mazzoletti; Camilla Taglietti; Gaia Navarra; Paola Savoia; Rossana Tiberio
Journal:  Medicina (Kaunas)       Date:  2020-05-22       Impact factor: 2.430

5.  Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies.

Authors:  Luca Degli Esposti; Valentina Perrone; Diego Sangiorgi; Stefano Buda; Margherita Andretta; Maurizio Rossini; Giampiero Girolomoni
Journal:  Biologics       Date:  2018-11-12

6.  Dimethyl fumarate treatment for psoriasis in a real-life setting: A multicentric retrospective study.

Authors:  Monica Corazza; Giulia Odorici; Andrea Conti; Vito Di Lernia; Alberico Motolese; Federico Bardazzi; Sergio Di Nuzzo; Alberto Monti; Federica Arginelli; Federica Filippi; Giorgia Valpiani; Chiara Morotti; Alessandro Borghi
Journal:  Dermatol Ther       Date:  2021-08-02       Impact factor: 3.858

7.  COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration.

Authors:  Nicola Luigi Bragazzi; Matteo Riccò; Alessia Pacifico; Piergiorgio Malagoli; Khalaf Kridin; Paolo Pigatto; Giovanni Damiani
Journal:  Dermatol Ther       Date:  2020-05-28       Impact factor: 2.851

8.  Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?

Authors:  M Talamonti; L Tofani; L Bianchi; M Galluzzo
Journal:  Arch Dermatol Res       Date:  2020-07-09       Impact factor: 3.017

9.  Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in Sardinia (Italy).

Authors:  L Atzori; C Mugheddu; G Addis; S Sanna; R Satta; C Ferreli; M G Atzori; M A Montesu; F Rongioletti
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-04       Impact factor: 9.228

10.  COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.

Authors:  Federica Filippi; Camilla Loi; Valeria Evangelista; Federico Bardazzi
Journal:  Dermatol Ther       Date:  2020-07-13       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.